Dow Jones Top Financial Services Headlines at 12 AM ET: Wells Fargo Faces Regulator Probe Over Efforts to Boost Black Homeownership | Ripple, ...
Dow Jones2026/10/08 04:00Wells Fargo Faces Regulator Probe Over Efforts to Boost Black Homeownership Trump's Housing and Urban Development is seeking to crack down on race-based lending, calling it a potential violation of the Fair Housing Act. ---- Ripple, Crypto's Payments Giant, Breaks Into Wall Street The crypto firm is emerging as a serious player in financing leveraged ETFs, a lucrative business long dominated by big banks. ---- Venture Firm Behind Chip Startup Groq Targets $10 Billion Megafund Winning bets on hot AI startups are vaulting a little-known Dallas firm into a small group of firms raising gigantic funds. ---- How one trend-following fund outperformed rivals by bringing humans back into the decision-making process One trend-following fund has outperformed rivals this year by deciding to take profits. ---- Financial Services Roundup: Market Talk Find insight on HSBC Holdings, BBVA, Standard Life and more in the latest Market Talks covering financial services. ---- Wall Street Bonuses Are Expected to Hit Another High This Year New York reports that the industry is now on pace for $90 billion in profits this year, leading to higher compensation. ---- Fintech Plaid Bets on Credit Scores to Fuel Next Phase of Growth EXCLUSIVE: Plaid is doubling down on its credit-scoring business with new AI models as the company aims to chart its next era of growth with a suite of products beyond its core business. ---- Companies Raise More Than $1 Trillion in Equity Markets, But AI, Bond Yields Sour Mood Markets had been expecting a bumper quarter following an ebullient start to the year crowned by SpaceX's record-breaking IPO. ---- Forbion Raises $2.6 Billion in Boost to European Biotech Industry Dutch haul comes despite European drugmakers and investors warning the region is losing ground. ---- Hackers Use Chinese AI Tool to Hit South Korean Banks, Exposing New Risk The attacks were the latest to highlight the vulnerability of even hardened targets to hackers using freely available artificial-intelligence tools. ---- KKR Strikes Deal to B
Wells Fargo Faces Regulator Probe Over Efforts to Boost Black Homeownership
Trump's Housing and Urban Development is seeking to crack down on race-based lending, calling it a potential violation of the Fair Housing Act.
----
Ripple, Crypto's Payments Giant, Breaks Into Wall Street
The crypto firm is emerging as a serious player in financing leveraged ETFs, a lucrative business long dominated by big banks.
----
Venture Firm Behind Chip Startup Groq Targets $10 Billion Megafund
Winning bets on hot AI startups are vaulting a little-known Dallas firm into a small group of firms raising gigantic funds.
----
How one trend-following fund outperformed rivals by bringing humans back into the decision-making process
One trend-following fund has outperformed rivals this year by deciding to take profits.
----
Financial Services Roundup: Market Talk
Find insight on HSBC Holdings, BBVA, Standard Life and more in the latest Market Talks covering financial services.
----
Wall Street Bonuses Are Expected to Hit Another High This Year
New York reports that the industry is now on pace for $90 billion in profits this year, leading to higher compensation.
----
Fintech Plaid Bets on Credit Scores to Fuel Next Phase of Growth
EXCLUSIVE: Plaid is doubling down on its credit-scoring business with new AI models as the company aims to chart its next era of growth with a suite of products beyond its core business.
----
Companies Raise More Than $1 Trillion in Equity Markets, But AI, Bond Yields Sour Mood
Markets had been expecting a bumper quarter following an ebullient start to the year crowned by SpaceX's record-breaking IPO.
----
Forbion Raises $2.6 Billion in Boost to European Biotech Industry
Dutch haul comes despite European drugmakers and investors warning the region is losing ground.
----
Hackers Use Chinese AI Tool to Hit South Korean Banks, Exposing New Risk
The attacks were the latest to highlight the vulnerability of even hardened targets to hackers using freely available artificial-intelligence tools.
----
KKR Strikes Deal to Buy Private-Capital Fund Administrator Gen II
Private-capital funds have proliferated in recent years as investors seek to reduce reliance on public markets.
----
NYSE Owner Launches Gold Futures in London
The contract began trading Monday alongside new futures for silver, platinum and palladium.
(END) Dow Jones Newswires
October 08, 2026 00:00 ET (04:00 GMT)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Fed Governor Waller leaves room for hawkishness: More rate hikes are needed to support inflation decline, not necessarily on a monthly basis.
Federal Reserve Governor Waller stated that if the data meets expectations, there will be further interest rate hikes. The core PCE year-on-year rate at 3% is still too high, and the recent monetary policy focus remains on fighting inflation.
Updated: Viatris will acquire pain therapy manufacturer Pacira BioSciences for 1.65 billions dollars.
The second paragraph adds stock information, while the fifth, eighth, and ninth paragraphs provide additional details. Background information is supplemented in the sixth, seventh, tenth, and eleventh paragraphs. Reuters, October 8 – Pharmaceutical company Viatris (VTRS.O) will acquire Pacira BioSciences (PCRX.O) in an all-cash deal worth $1.65 billions, adding two non-opioid painkillers to its portfolio, the companies said on Thursday. Viatris will acquire Pacira at $36.50 per share, representing a 44.8% premium to the latest closing price. Pacira’s stock rose by 44% in premarket trading. Pacira’s non-opioid painkillers, Exparel and Zilretta, generated sales in 2025 of $575.1 millions and $116.6 millions respectively. Exparel is used to relieve acute pain after surgery, and Zilretta is used to treat pain associated with knee osteoarthritis. Viatris stated it expects to expand the reach of these products in selected target markets. Viatris CEO Scott Smith stated, “the addition of these medications creates a synergy with our rapid-acting meloxicam market opportunities, positioning us as a leader in non-opioid pain management.” The US Food and Drug Administration (FDA) is expected to make a decision by December 27 on the approval application for rapid-acting meloxicam for the treatment of moderate to severe acute pain. Viatris plans to finance the acquisition primarily with idle cash, and the remainder through short-term borrowing. The company noted the deal will have minimal impact on its total leverage ratio. In August, Viatris (link) raised its annual adjusted profit forecast, counting on strong brand drug sales and growth in the Chinese market. The pharmaceutical company had previously faced (link) production setbacks in its Indian operations, including a fire at its Nashik plant in western India and increased competition in the generic drug market, raising concerns about the resilience and growth of its core business. The company stated the transaction is expected to close by the end of 2026 and will immediately enhance Viatris’s financial guidance metrics. (For non-native English speakers, Reuters provides automated translations of its reports into several other languages. Since automated translations may contain errors or lack necessary context, Reuters does not guarantee their accuracy and provides them for convenience only. Reuters accepts no liability for any damage or loss caused by the use of automated translation.)
Oppenheimer Adjusts Acuity Price Target to $415 From $440, Maintains Outperform Rating
08:51 AM EDT, 10/08/2026 (MT Newswires) -- Acuity Brands (AYI) has an average rating of overweight and mean price target of $400.57, according to analysts polled by FactSet. (MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www.mtnewswires.com/contact-us)
BUZZ-Pacira BioSciences stock surges on Viatris' $1.65 billion acquisition deal
On October 8, Pacira BioSciences (PCRX.O) shares rose 44% in pre-market trading to $36.30 as Viatris (VTRS.O) announced it will acquire Pacira BioSciences for $1.65 billion in cash, at a price of $36.50 per share. This offer represents a premium of approximately 44.8% over Pacira's last closing price of $25.20. The transaction will add Pacira’s non-opioid pain medications Exparel and Zilretta to Viatris’ product portfolio. Both parties expect the deal to be completed by the end of 2026. As of the previous trading day’s close, PCRX was down 2.6% year-to-date.
Crypto prices
More
